A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development

Journal of Immunology

Volumn 186, Issue 3, 2011, Pages 1399-1410

  Bemark, Mats ^a   Bergqvist, Peter ^a   Stensson, Anneli ^a   Holmberg, Anna ^a   Mattsson, Johan ^a   Lycke, Nils Y ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 NITROPHENYL ACETYL CHICKEN GAMMAGLOBULIN; ALUMINUM POTASSIUM SULFATE; B7 ANTIGEN; CD19 ANTIGEN; CHOLERA TOXIN; CHOLERA TOXIN A1 DD; HYBRID PROTEIN; IMJECT ALUM; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; RIBI; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW; CELL MATURATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; FEMALE; GERMINAL CENTER; IMMUNOLOGICAL MEMORY; MEMORY CELL; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; B-LYMPHOCYTE SUBSETS; CELL DIFFERENTIATION; CELL WALL SKELETON; CHOLERA TOXIN; CORD FACTORS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GERMINAL CENTER; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; LIPID A; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PLASMA CELLS; RECOMBINANT FUSION PROTEINS; TIME FACTORS;

EID: 79251591958     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002881     Document Type: Article

References (61)

1. Ahmed, R., and D. Gray. 1996. Immunological memory and protective immunity: understanding their relation. Science 272: 54-60. (Pubitemid 26110754)
2. Amanna, I. J., N. E. Carlson, and M. K. Slifka. 2007. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357: 1903-1915.
3. Castellino, F., G. Galli, G. Del Giudice, and R. Rappuoli. 2009. Generating memory with vaccination. Eur. J. Immunol. 39: 2100-2105.
4. Tangye, S. G., and D. M. Tarlinton. 2009. Memory B cells: effectors of long-lived immune responses. Eur. J. Immunol. 39: 2065-2075.
5. Ott, G., and G. van Nest. 2006. Development of vaccine adjuvants: a historical perspective. In Vaccine Adjuvants and Delivery Systems. M. Singh, ed. John Wiley & Sons, Hoboken, NJ, p. 1-31.
6. Pulendran, B., and R. Ahmed. 2006. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124: 849-863.
7. Lambrecht, B. N., M. Kool, M. A. Willart, and H. Hammad. 2009. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21: 23-29.
8. Pulendran, B. 2009. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9: 741-747.
9. Galli, G., D. Medini, E. Borgogni, L. Zedda, M. Bardelli, C. Malzone, S. Nuti, S. Tavarini, C. Sammicheli, A. K. Hilbert, et al. 2009. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. USA 106: 3877-3882.
10. Vieira, P., and K. Rajewsky. 1990. Persistence of memory B cells in mice deprived of T cell help. Int. Immunol. 2: 487-494.
11. Cancro, M. P. 2010. The persistence of memory: a unique niche for IgG memory B cells. Proc. Natl. Acad. Sci. USA 107: 12737-12738.
12. Bernasconi, N. L., N. Onai, and A. Lanzavecchia. 2003. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101: 4500-4504.
13. Richard, K., S. K. Pierce, and W. Song. 2008. The agonists of TLR4 and 9 are sufficient to activate memory B cells to differentiate into plasma cells in vitro but not in vivo. J. Immunol. 181: 1746-1752.
14. Benson, M. J., R. Elgueta, W. Schpero, M. Molloy, W. Zhang, E. Usherwood, and R. J. Noelle. 2009. Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals. J. Exp. Med. 206: 2013-2025.
15. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
16. Bendelac, A., and R. Medzhitov. 2002. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J. Exp. Med. 195: F19-F23.
17. Allen, C. D., T. Okada, and J. G. Cyster. 2007. Germinal-center organization and cellular dynamics. Immunity 27: 190-202.
18. Lindquist, R. L., G. Shakhar, D. Dudziak, H. Wardemann, T. Eisenreich, M. L. Dustin, and M. C. Nussenzweig. 2004. Visualizing dendritic cell networks in vivo. Nat. Immunol. 5: 1243-1250.
19. Kool, M., T. Soullié, M. van Nimwegen, M. A. Willart, F. Muskens, S. Jung, H. C. Hoogsteden, H. Hammad, and B. N. Lambrecht. 2008. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205: 869-882.
20. Li, H., S. Nookala, and F. Re. 2007. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J. Immunol. 178: 5271-5276. (Pubitemid 46595312)
21. Lycke, N. 2006. Mechanisms of adjuvant action. In Vaccine Adjuvants and Delivery Systems. M. Singh, ed. John Wiley & Sons, Hoboken, NJ, p. 53-79.
22. Holmgren, J., and C. Czerkinsky. 2005. Mucosal immunity and vaccines. Nat. Med. 11(4, Suppl): S45-S53.
23. Agren, L. C., L. Ekman, B. Löwenadler, and N. Y. Lycke. 1997. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158: 3936-3946.
24. Agren, L., E. Sverremark, L. Ekman, K. Schön, B. Löwenadler, C. Fernandez, and N. Lycke. 2000. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving antiapoptotic Bcl-2- and germinal center-promoting effects. J. Immunol. 164: 6276-6286.
25. Eriksson, A. M., K. M. Schön, and N. Y. Lycke. 2004. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. 173: 3310-3319.
26. Fujihashi, K., T. Koga, F. W. van Ginkel, Y. Hagiwara, and J. R. McGhee. 2002. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20: 2431-2438.
27. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350: 896-903.
28. Lycke, N. 2005. Targeted vaccine adjuvants based on modified cholera toxin. Curr. Mol. Med. 5: 591-597.
29. Sundling, C., K. Schön, A. Mörner, M. N. Forsell, R. T. Wyatt, R. Thorstensson, G. B. Karlsson Hedestam, and N. Y. Lycke. 2008. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J. Gen. Virol. 89: 2954-2964.
30. Plotkin, S. A. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47: 401-409.
31. Eichelberger, M., H. Golding, M. Hess, J. Weir, K. Subbarao, C. J. Luke, M. Friede, and D. Wood. 2008. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 26: 4299-4303.
32. Delgado, M. F., S. Coviello, A. C. Monsalvo, G. A. Melendi, J. Z. Hernandez, J. P. Batalle, L. Diaz, A. Trento, H. Y. Chang, W. Mitzner, et al. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15: 34-41.
33. Dörner, T., and A. Radbruch. 2007. Antibodies and B cell memory in viral immunity. Immunity 27: 384-392. (Pubitemid 47418684)
34. Klein, U., and R. Dalla-Favera. 2008. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 8: 22-33.
35. McHeyzer-Williams, L. J., and M. G. McHeyzer-Williams. 2005. Antigen-specific memory B cell development. Annu. Rev. Immunol. 23: 487-513.
36. Ahuja, A., S. M. Anderson, A. Khalil, and M. J. Shlomchik. 2008. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl. Acad. Sci. USA 105: 4802-4807.
37. Bernasconi, N. L., E. Traggiai, and A. Lanzavecchia. 2002. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298: 2199-2202.
38. Gatto, D., T. Pfister, A. Jegerlehner, S. W. Martin, M. Kopf, and M. F. Bachmann. 2005. Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J. Exp. Med. 201: 993-1005.
39. Todd, D. J., L. J. McHeyzer-Williams, C. Kowal, A. H. Lee, B. T. Volpe, B. Diamond, M. G. McHeyzer-Williams, and L. H. Glimcher. 2009. XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development. J. Exp. Med. 206: 2151-2159.
40. Klein, U., K. Rajewsky, and R. Küppers. 1998. Human immunoglobulin (Ig)M+ IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188: 1679-1689.
41. Driver, D. J., L. J. McHeyzer-Williams, M. Cool, D. B. Stetson, and M. G. McHeyzer-Williams. 2001. Development and maintenance of a B220- memory B cell compartment. J. Immunol. 167: 1393-1405.
42. Anderson, S. M., M. M. Tomayko, A. Ahuja, A. M. Haberman, and M. J. Shlomchik. 2007. New markers for murine memory B cells that define mutated and unmutated subsets. J. Exp. Med. 204: 2103-2114.
43. Dogan, I., B. Bertocci, V. Vilmont, F. Delbos, J. Mégret, S. Storck, C. A. Reynaud, and J. C. Weill. 2009. Multiple layers of B cell memory with different effector functions. Nat. Immunol. 10: 1292-1299.
44. Weiss, U., and K. Rajewsky. 1990. The repertoire of somatic antibody mutants accumulating in the memory compartment after primary immunization is restricted through affinity maturation and mirrors that expressed in the secondary response. J. Exp. Med. 172: 1681-1689.
45. Agren, L. C., L. Ekman, B. Löwenadler, J. G. Nedrud, and N. Y. Lycke. 1999. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162: 2432-2440.
46. Nossal, G. J., M. Karvelas, and B. Pulendran. 1993. Soluble antigen profoundly reduces memory B-cell numbers even when given after challenge immunization. Proc. Natl. Acad. Sci. USA 90: 3088-3092.
47. Cumano, A., and K. Rajewsky. 1986. Clonal recruitment and somatic mutation in the generation of immunological memory to the hapten NP. EMBO J. 5: 2459-2468.
48. Berek, C., and C. Milstein. 1987. Mutation drift and repertoire shift in the maturation of the immune response. Immunol. Rev. 96: 23-41.
49. Eliasson, D. G., K. El Bakkouri, K. Schön, A. Ramne, E. Festjens, B. Löwenadler, W. Fiers, X. Saelens, and N. Lycke. 2008. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26: 1243-1252.
50. Good-Jacobson, K. L., C. G. Szumilas, L. Chen, A. H. Sharpe, M. M. Tomayko, and M. J. Shlomchik. 2010. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat. Immunol. 11: 535-542.
51. Zotos, D., J. M. Coquet, Y. Zhang, A. Light, K. D'Costa, A. Kallies, L. M. Corcoran, D. I. Godfrey, K. M. Toellner, M. J. Smyth, et al. 2010. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J. Exp. Med. 207: 365-378.
52. O'Connor, B. P., M. Cascalho, and R. J. Noelle. 2002. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J. Exp. Med. 195: 737-745.
53. Allen, C. D., K. M. Ansel, C. Low, R. Lesley, H. Tamamura, N. Fujii, and J. G. Cyster. 2004. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat. Immunol. 5: 943-952.
54. Hoyer, B. F., I. M. Mumtaz, T. Yoshida, F. Hiepe, and A. Radbruch. 2008. How to cope with pathogenic long-lived plasma cells in autoimmune diseases. Ann. Rheum. Dis. 67(Suppl 3): iii87-iii89.
55. Shi, G. X., K. Harrison, G. L. Wilson, C. Moratz, and J. H. Kehrl. 2002. RGS13 regulates germinal center B lymphocytes responsiveness to CXC chemokine ligand (CXCL)12 and CXCL13. J. Immunol. 169: 2507-2515.
56. Gatto, D., D. Paus, A. Basten, C. R. Mackay, and R. Brink. 2009. Guidance of B cells by the orphan G protein-coupled receptor EBI2 shapes humoral immune responses. Immunity 31: 259-269.
57. Anderson, S. M., A. Khalil, M. Uduman, U. Hershberg, Y. Louzoun, A. M. Haberman, S. H. Kleinstein, and M. J. Shlomchik. 2009. Taking advantage: high-affinity B cells in the germinal center have lower death rates, but similar rates of division, compared to low-affinity cells. J. Immunol. 183: 7314-7325.
58. Rahman, Z. S., and T. Manser. 2004. B cells expressing Bcl-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. J. Immunol. 173: 6179-6188.
59. White, H., and D. Gray. 2000. Analysis of immunoglobulin (Ig) isotype diversity and IgM/D memory in the response to phenyl-oxazolone. J. Exp. Med. 191: 2209-2220.
60. Slifka, M. K., and R. Ahmed. 1998. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 10: 252-258.
61. Radbruch, A., G. Muehlinghaus, E. O. Luger, A. Inamine, K. G. Smith, T. Dörner, and F. Hiepe. 2006. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6: 741-750.